Surgical resection of rare esophageal cancers

Sahar A. Saddoughi, Jim Taswell, William S. Harmsen, Matthew L. Inra, Shanda H. Blackmon, Francis C. Nichols, Stephen D. Cassivi, Dennis A Wigle, K. Robert Shen, Mark S. Allen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background Although surgical resection of adenocarcinoma or squamous cell carcinoma of the esophagus is standard practice, the treatment strategy for other malignant rare esophageal cancers is still under debate. The aim of this study was to examine the treatment of rare malignant esophageal cancers and to evaluate the survival of these patients. Methods A retrospective review of all esophagectomies performed at Mayo Clinic from 1980 to 2014 (approximately 4,000 cases) identified 24 patients with histologic features other than adenocarcinoma or squamous cell carcinoma. Their medical records were reviewed for demographics, presenting symptoMS evaluation, surgical management, pathologic features, and short-term and long-term outcome. Results Pathologic identifications included small cell carcinoma, lymphoma, and undifferentiated carcinoma in 4 (16.7%) patients each and neuroendocrine, melanoma, leiomyosarcoma, sarcomatoid, sarcoma, and gastrointestinal stromal tumor in 2 (8.3%) patients each. The most common presenting symptoms included dysphasia in 91.7% patients (22/24), pain in 75.0% (18/24), and weight loss in 62.5% (15/24). Preoperative evaluation included barium swallow in 91.7% (22/24), computed tomography in 91.7% (22/24), positron emission tomography in 54.2% (13/24), esophagogastroduodenoscopy in 100% (24/24), and endoscopic ultrasonography in 29.2% (7/24) patients. The location of the tumor was at the gastroesophageal junction in 41.7% (10/24). There was no operative mortality, and 13 patients (54.16%) had at least one postoperative adverse event. The 1-year survival after esophagectomy was 69.7%, the 5-year survival was 42.7%, and the 10-year survival was 37.4%. Conclusions Esophageal cancer with pathologic features other than squamous cell carcinoma or adenocarcinoma is rare. Esophagectomy for rare types of malignant esophageal cancers should be considered part of the effective treatment paradigm.

Original languageEnglish (US)
Pages (from-to)311-315
Number of pages5
JournalAnnals of Thoracic Surgery
Volume101
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Esophageal Neoplasms
Esophagectomy
Squamous Cell Carcinoma
Adenocarcinoma
Survival
Digestive System Endoscopy
Esophagogastric Junction
Endosonography
Gastrointestinal Stromal Tumors
Small Cell Carcinoma
Symptom Assessment
Leiomyosarcoma
Aphasia
B-Cell Chronic Lymphocytic Leukemia
Barium
Deglutition
Sarcoma
Positron-Emission Tomography
Esophagus
Medical Records

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Saddoughi, S. A., Taswell, J., Harmsen, W. S., Inra, M. L., Blackmon, S. H., Nichols, F. C., ... Allen, M. S. (2016). Surgical resection of rare esophageal cancers. Annals of Thoracic Surgery, 101(1), 311-315. https://doi.org/10.1016/j.athoracsur.2015.06.015

Surgical resection of rare esophageal cancers. / Saddoughi, Sahar A.; Taswell, Jim; Harmsen, William S.; Inra, Matthew L.; Blackmon, Shanda H.; Nichols, Francis C.; Cassivi, Stephen D.; Wigle, Dennis A; Shen, K. Robert; Allen, Mark S.

In: Annals of Thoracic Surgery, Vol. 101, No. 1, 01.01.2016, p. 311-315.

Research output: Contribution to journalArticle

Saddoughi, SA, Taswell, J, Harmsen, WS, Inra, ML, Blackmon, SH, Nichols, FC, Cassivi, SD, Wigle, DA, Shen, KR & Allen, MS 2016, 'Surgical resection of rare esophageal cancers', Annals of Thoracic Surgery, vol. 101, no. 1, pp. 311-315. https://doi.org/10.1016/j.athoracsur.2015.06.015
Saddoughi SA, Taswell J, Harmsen WS, Inra ML, Blackmon SH, Nichols FC et al. Surgical resection of rare esophageal cancers. Annals of Thoracic Surgery. 2016 Jan 1;101(1):311-315. https://doi.org/10.1016/j.athoracsur.2015.06.015
Saddoughi, Sahar A. ; Taswell, Jim ; Harmsen, William S. ; Inra, Matthew L. ; Blackmon, Shanda H. ; Nichols, Francis C. ; Cassivi, Stephen D. ; Wigle, Dennis A ; Shen, K. Robert ; Allen, Mark S. / Surgical resection of rare esophageal cancers. In: Annals of Thoracic Surgery. 2016 ; Vol. 101, No. 1. pp. 311-315.
@article{9f8fe39ae19d478a8a1770ad571a24a9,
title = "Surgical resection of rare esophageal cancers",
abstract = "Background Although surgical resection of adenocarcinoma or squamous cell carcinoma of the esophagus is standard practice, the treatment strategy for other malignant rare esophageal cancers is still under debate. The aim of this study was to examine the treatment of rare malignant esophageal cancers and to evaluate the survival of these patients. Methods A retrospective review of all esophagectomies performed at Mayo Clinic from 1980 to 2014 (approximately 4,000 cases) identified 24 patients with histologic features other than adenocarcinoma or squamous cell carcinoma. Their medical records were reviewed for demographics, presenting symptoMS evaluation, surgical management, pathologic features, and short-term and long-term outcome. Results Pathologic identifications included small cell carcinoma, lymphoma, and undifferentiated carcinoma in 4 (16.7{\%}) patients each and neuroendocrine, melanoma, leiomyosarcoma, sarcomatoid, sarcoma, and gastrointestinal stromal tumor in 2 (8.3{\%}) patients each. The most common presenting symptoms included dysphasia in 91.7{\%} patients (22/24), pain in 75.0{\%} (18/24), and weight loss in 62.5{\%} (15/24). Preoperative evaluation included barium swallow in 91.7{\%} (22/24), computed tomography in 91.7{\%} (22/24), positron emission tomography in 54.2{\%} (13/24), esophagogastroduodenoscopy in 100{\%} (24/24), and endoscopic ultrasonography in 29.2{\%} (7/24) patients. The location of the tumor was at the gastroesophageal junction in 41.7{\%} (10/24). There was no operative mortality, and 13 patients (54.16{\%}) had at least one postoperative adverse event. The 1-year survival after esophagectomy was 69.7{\%}, the 5-year survival was 42.7{\%}, and the 10-year survival was 37.4{\%}. Conclusions Esophageal cancer with pathologic features other than squamous cell carcinoma or adenocarcinoma is rare. Esophagectomy for rare types of malignant esophageal cancers should be considered part of the effective treatment paradigm.",
author = "Saddoughi, {Sahar A.} and Jim Taswell and Harmsen, {William S.} and Inra, {Matthew L.} and Blackmon, {Shanda H.} and Nichols, {Francis C.} and Cassivi, {Stephen D.} and Wigle, {Dennis A} and Shen, {K. Robert} and Allen, {Mark S.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.athoracsur.2015.06.015",
language = "English (US)",
volume = "101",
pages = "311--315",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Surgical resection of rare esophageal cancers

AU - Saddoughi, Sahar A.

AU - Taswell, Jim

AU - Harmsen, William S.

AU - Inra, Matthew L.

AU - Blackmon, Shanda H.

AU - Nichols, Francis C.

AU - Cassivi, Stephen D.

AU - Wigle, Dennis A

AU - Shen, K. Robert

AU - Allen, Mark S.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background Although surgical resection of adenocarcinoma or squamous cell carcinoma of the esophagus is standard practice, the treatment strategy for other malignant rare esophageal cancers is still under debate. The aim of this study was to examine the treatment of rare malignant esophageal cancers and to evaluate the survival of these patients. Methods A retrospective review of all esophagectomies performed at Mayo Clinic from 1980 to 2014 (approximately 4,000 cases) identified 24 patients with histologic features other than adenocarcinoma or squamous cell carcinoma. Their medical records were reviewed for demographics, presenting symptoMS evaluation, surgical management, pathologic features, and short-term and long-term outcome. Results Pathologic identifications included small cell carcinoma, lymphoma, and undifferentiated carcinoma in 4 (16.7%) patients each and neuroendocrine, melanoma, leiomyosarcoma, sarcomatoid, sarcoma, and gastrointestinal stromal tumor in 2 (8.3%) patients each. The most common presenting symptoms included dysphasia in 91.7% patients (22/24), pain in 75.0% (18/24), and weight loss in 62.5% (15/24). Preoperative evaluation included barium swallow in 91.7% (22/24), computed tomography in 91.7% (22/24), positron emission tomography in 54.2% (13/24), esophagogastroduodenoscopy in 100% (24/24), and endoscopic ultrasonography in 29.2% (7/24) patients. The location of the tumor was at the gastroesophageal junction in 41.7% (10/24). There was no operative mortality, and 13 patients (54.16%) had at least one postoperative adverse event. The 1-year survival after esophagectomy was 69.7%, the 5-year survival was 42.7%, and the 10-year survival was 37.4%. Conclusions Esophageal cancer with pathologic features other than squamous cell carcinoma or adenocarcinoma is rare. Esophagectomy for rare types of malignant esophageal cancers should be considered part of the effective treatment paradigm.

AB - Background Although surgical resection of adenocarcinoma or squamous cell carcinoma of the esophagus is standard practice, the treatment strategy for other malignant rare esophageal cancers is still under debate. The aim of this study was to examine the treatment of rare malignant esophageal cancers and to evaluate the survival of these patients. Methods A retrospective review of all esophagectomies performed at Mayo Clinic from 1980 to 2014 (approximately 4,000 cases) identified 24 patients with histologic features other than adenocarcinoma or squamous cell carcinoma. Their medical records were reviewed for demographics, presenting symptoMS evaluation, surgical management, pathologic features, and short-term and long-term outcome. Results Pathologic identifications included small cell carcinoma, lymphoma, and undifferentiated carcinoma in 4 (16.7%) patients each and neuroendocrine, melanoma, leiomyosarcoma, sarcomatoid, sarcoma, and gastrointestinal stromal tumor in 2 (8.3%) patients each. The most common presenting symptoms included dysphasia in 91.7% patients (22/24), pain in 75.0% (18/24), and weight loss in 62.5% (15/24). Preoperative evaluation included barium swallow in 91.7% (22/24), computed tomography in 91.7% (22/24), positron emission tomography in 54.2% (13/24), esophagogastroduodenoscopy in 100% (24/24), and endoscopic ultrasonography in 29.2% (7/24) patients. The location of the tumor was at the gastroesophageal junction in 41.7% (10/24). There was no operative mortality, and 13 patients (54.16%) had at least one postoperative adverse event. The 1-year survival after esophagectomy was 69.7%, the 5-year survival was 42.7%, and the 10-year survival was 37.4%. Conclusions Esophageal cancer with pathologic features other than squamous cell carcinoma or adenocarcinoma is rare. Esophagectomy for rare types of malignant esophageal cancers should be considered part of the effective treatment paradigm.

UR - http://www.scopus.com/inward/record.url?scp=84955669414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955669414&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2015.06.015

DO - 10.1016/j.athoracsur.2015.06.015

M3 - Article

C2 - 26277558

AN - SCOPUS:84955669414

VL - 101

SP - 311

EP - 315

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 1

ER -